Related Experiment Videos
Acyl dipeptides as reversible caspase inhibitors. Part 2: further optimization.
Steven D Linton1, Donald S Karanewsky, Robert J Ternansky
1Idun Pharmaceuticals, Inc., 9380 Judicial Drive, San Diego, CA 92121, USA. slinton@idun.com
Bioorganic & Medicinal Chemistry Letters
|September 25, 2002
Summary
Researchers developed novel broad spectrum caspase inhibitors with potent activity against caspases 1, 3, 6, 7, and 8. The lead compound demonstrated significant low nanomolar inhibition, especially against caspase 8.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Drug Discovery
Background:
- Caspases are critical proteases involved in apoptosis and inflammation.
- Broad spectrum caspase inhibitors are sought for therapeutic applications.
- Previous inhibitor classes have limitations.
Purpose of the Study:
- To discover and optimize a new structural class of broad spectrum caspase inhibitors.
- To evaluate the inhibitory activity against key caspases (1, 3, 6, 7, and 8).
Main Methods:
- Synthesis and structural optimization of novel chemical entities.
- In vitro enzymatic assays to determine inhibitory concentrations (IC50 values).
- Profiling against a panel of recombinant human caspases.
Main Results:
- A new structural class of broad spectrum caspase inhibitors was identified.
- The most potent compound exhibited low nanomolar activity against caspases 1, 3, 6, 7, and 8.
- Single-digit nanomolar inhibitory potency was achieved specifically against caspase 8.
Conclusions:
- The novel inhibitor class shows promising broad spectrum caspase inhibitory potential.
- The lead compound represents a significant advancement in caspase inhibitor development.
- Further investigation is warranted for therapeutic development.